Anixa Biosciences and Cleveland Clinic to Present Additional Data From Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Anixa Biosciences and Cleveland Clinic to Present Additional Data From Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif., Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas, from November 6-10, 2024. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense. The presentation, titled "Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC," will be presented by Dr. Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic.
2024年10月28日,位於加利福尼亞州聖何塞的anixa biosciences股份有限公司("anixa"或"公司")(納斯達克:ANIX),一家專注於抗癌醫藥的生物技術公司,今天宣佈將在海豐國際免疫治療學會(SITC)第39屆年會上展示其乳腺癌疫苗的第一階段臨床試驗的額外數據。本次年會將於2024年11月6日至10日在線上和德克薩斯州休斯頓同時舉行。該試驗由克利夫蘭診所與美國國防部的資助合作進行。報告題爲"alpha-乳清蛋白疫苗在具有高風險可手術的三陰性乳腺癌(TNBC)和高遺傳風險患者的一期試驗",將由克利夫蘭診所FDA/IND試驗計劃經理Emily Rhoades博士進行演講。
Details of the poster presentation can be found below:
海報展示的詳細內容如下:
Poster Title: Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC
海報標題:alpha-乳清蛋白疫苗在具有高風險可手術的三陰性乳腺癌(TNBC)和高遺傳風險患者的一期試驗
Abstract #: 631
摘要編號:631
Date/Time: November 8, 2024, 12:15 p.m. CT
日期/時間:2024年11月8日,中部標準時間下午12:15
After the data is presented, Anixa will make the poster presentation available on its website and through a public announcement.
數據展示後,anixa將在其網站上公佈海報展示內容,並通過公告進行公開。
About Anixa Bioscience's Breast Cancer Vaccine
Anixa's breast cancer vaccine takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in certain breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing.
關於Anixa Bioscience的乳腺癌疫苗
Anixa的乳腺癌疫苗利用在生命中某些時期具有特定功能的內源性產生的蛋白質,然後這些蛋白質會「退役」並從身體中消失。其中一種蛋白質是一種乳腺特異性泌乳蛋白,α-乳白蛋白,在正常的老化組織中已不再存在於斷奶後,但在某些乳腺癌中存在。激活對這種「退役」蛋白的免疫系統可提供對錶達α-乳白蛋白的新近乳腺瘤的預防性免疫保護。疫苗還含有一個激活先天免疫反應的佐劑,這使免疫系統能夠對新近腫瘤產生反應,以防止它們生長。
Initial Phase 1 data was presented at the San Antonio Breast Cancer Symposium in December 2023. The data showed no safety concerns, with protocol defined immune responses observed in a majority of patients.
初期1期數據於2023年12月在聖安東尼奧乳腺癌研討會上進行了報告。數據顯示,大多數患者中觀察到了符合協議定義的免疫應答,並且未出現安全問題。
The Phase 1 trial is conducted in collaboration with Cleveland Clinic and is funded by a grant from the U.S. Department of Defense. Anixa is the exclusive worldwide licensee of the novel breast cancer vaccine technology developed at Cleveland Clinic. The grant funding from the U.S. Department of Defense was provided to Cleveland Clinic.
第1期試驗與克利夫蘭診所合作進行,並由美國國防部的撥款資助。Anixa是在克利夫蘭診所開發的新型乳腺癌疫苗技術的獨家全球許可證持有人。美國國防部的撥款資金是提供給克利夫蘭診所的。
This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Cleveland Clinic exclusively licensed this technology to Anixa Biosciences. The Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company.
這種疫苗技術是由已故的文森特•圖西博士發明的,他是克利夫蘭診所萊納研究所炎症與免疫科的莫特和艾瑞斯・諾維默特色椅子創新乳腺癌研究教授。克利夫蘭診所獨家向Anixa Biosciences許可了這項技術。克利夫蘭診所有權從公司獲得版稅和其他商業化收入。
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Anixa生物科學公司(Anixa Biosciences)
anixa biosciences是一家專注於治療和預防癌症的臨床階段生物技術公司。anixa的治療組合包括與莫菲特癌症中心合作開發的卵巢癌免疫療法計劃,該計劃使用一種新型CAR-t,被稱爲嵌合內分泌受體-t細胞(CER-T)技術。該公司的疫苗組合包括與克利夫蘭診所合作開發的疫苗,用於治療和預防乳腺癌和卵巢癌,以及用來應對許多不治之症癌症的其他癌症疫苗,包括肺癌、結腸癌和前列腺癌的高發性惡性腫瘤。這些疫苗技術專注於免疫化"退役"蛋白質,已發現這些蛋白質在某些癌症中表達。anixa獨特的商業模式是與世界知名研究機構合作開發的各個階段,使該公司能夠持續審查相關領域的新興技術以進行進一步的開發和商業化。欲了解更多信息,請訪問網站或關注anixa的Twitter、LinkedIn、Facebook和YouTube。
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
前瞻性聲明
本新聞稿中不是歷史事實的聲明可被視爲美國《1995年私人證券訴訟改革法》中的前瞻性聲明。前瞻性聲明不是歷史事實的陳述,而是反映Anixa有關未來事件和結果的當前期望。我們通常使用「相信」,「預計」,「計劃」,「打算」,「預測」,「可能」,「將」等類似詞語來識別前瞻性聲明。這樣的前瞻性聲明,包括關於我們的預期,涉及風險,不確定性和其他因素的聲明,其中一些因素超出我們的控制,這可能導致我們的實際結果,績效或成就或行業成果與任何未來結果,績效或成就所反映的相比有實質性區別。我們的前瞻性聲明,包括有關我們的預期的聲明,涉及風險,不確定性和其他因素,其中一些因素在我們最近的年度報告的「項目1A - 風險因素」和其他章節,包括在我們的季度報告中提到 10-Q和當前的8-K報告。我們承諾不公開更新或修訂任何前瞻性聲明,無論是因爲獲得新信息,未來事件或其他原因,除非法律要求。在評估本新聞稿中所呈現的信息時,如果評估此類前瞻性聲明,應謹慎。
Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808
聯繫方式:
Mike Catelani
總裁,首席運營官兼首席財務官
[email protected]
408-708-9808
SOURCE Anixa Biosciences, Inc.
來源:anixa biosciences,Inc.